2

For paragraph (1) substitute—

1

Where principles and guidelines of good manufacturing practice have been published under, or apply by virtue of, regulation C17, which apply to an active substance manufactured in Great Britain, a manufacturer in Great Britain must comply with the principles and guidelines of good manufacturing practice for active substances.

1A

Where the Commission has adopted principles and guidelines of good manufacturing practice under the third paragraph of Article 47 of the 2001 Directive which applies to an active substance manufactured in Northern Ireland, a manufacturer in Northern Ireland must comply with the principles and guidelines of good manufacturing practice for active substances.

3

For paragraph (2) substitute—

2

Where principles and guidelines of good distribution practice have been published under, or apply by virtue of, regulation C17, which apply to an active substance distributed in Great Britain, a distributor in Great Britain must comply with the principles and guidelines of good distribution practice for active substances.

2A

Where the Commission has adopted principles and guidelines of good distribution practice under the fourth paragraph of Article 47 of the 2001 Directive which applies to an active substance distributed in the Northern Ireland, a distributor in Northern Ireland must comply with the principles and guidelines of good distribution practice for active substances.

4

In paragraph (3)—

a

for “the UK” substitute “ Northern Ireland ”;

b

for “from a third country” substitute “ into Northern Ireland from a country other than an EEA State ”;

c

for “exporting third country” in both places it occurs substitute “ exporting country ”;

d

in sub-paragraph (c)(ii), for “the Union” substitute “ Northern Ireland ”.

4A

After paragraph (3) insert—

3A

Without prejudice to regulation 37(4) and paragraph 9A of Schedule 8, where principles and guidelines of good manufacturing practice have been published under, or apply by virtue of, regulation C17, which apply to an active substance imported into Great Britain other than from Northern Ireland and where an active substance is so imported—

a

the importer must comply with good manufacturing practice and good distribution practice in relation to the active substance,

b

the active substances must have been manufactured in accordance with standards which are at least equivalent to good manufacturing practice, and

c

the active substances must be accompanied by a written confirmation from the competent authority of the exporting country of the following—

i

the standards of manufacturing practice applicable to the plant manufacturing the exported active substance are at least equivalent to good manufacturing practice,

ii

the manufacturing plant concerned is subject to regular, strict and transparent controls and to the effective enforcement of standards of manufacturing practice at least equivalent to good manufacturing practice, including repeated and unannounced inspections, so as to ensure a protection of public health at least equivalent to that in Great Britain, and

iii

in the event of findings relating to non-compliance, information on such findings is supplied by the exporting country to the licensing authority without any delay.

5

In paragraph (4)—

a

for “(3)(c) does” substitute “ (3)(c) and (3A)(c) do ”;

b

in sub-paragraph (a), after “Article 111b of the 2001 Directive” insert “ (in the case of an import into Northern Ireland) or paragraph (6) (in the case of an import into Great Britain) ”;

c

in sub-paragraph (b)(i), after “competent authority of a member State” insert “ or licensing authority (in the case of an import into Northern Ireland) or licensing authority or an appropriate authority responsible for the licensing of medicinal products in a country included in a list under paragraph (6) (in the case of an import into Great Britain) ”.